Drug Development Disruption
The skyrocketing costs of pharmaceutical drug development create a risk-averse culture in the industry. Ingmar shares a compelling example of how AI can drastically reduce testing efforts, suggesting innovative candidates that lead to significant breakthroughs. The conversation shifts to the effectiveness of shallow versus deep machine learning techniques, highlighting the potential for remarkable efficiency gains in drug discovery.In this clip
From this podcast
Super Data Science: ML & AI Podcast with Jon Krohn
739: AI is Eating Biology and Chemistry — with Dr. Ingmar Schuster
Related Questions
Can artificial intelligence and machine learning revolutionize medicine as discussed in the episode AI and Actionable Insights for Drug Development with Daphne Koller and the clip AI in Drug Discovery?
Why are deep learning models so expensive that only big players in tech can afford to develop them, as discussed in the episode SDS 483: Setting Yourself Apart in Data Science Interviews — with Andrew Jones and the clip MVP Mindset in AI?